araag2/HINT huggingface dataset:
Clinical trial NCT02741245 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: ezetimibe 10 mg, rosuvastatin 2.5 mg, placebo for ezetimibe, placebo for rosuvastatin
SMILES: O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Japanese

          -  Outpatient with hypercholesterolemia

          -  Female participant who is of reproductive potential has to agree to remain abstinent
             or use (or partner use) two acceptable methods of birth control from date of signed
             informed consent to the 14 days after the last dose of study drug

          -  Will maintain a stable diet that is consistent with the Japan Atherosclerosis Society
             Guideline 2012 (JAS 2012) for prevention of atherosclerotic cardiovascular diseases
             for the duration of the study

        Exclusion Criteria:

          -  Uncontrolled hypertension (treated or untreated)

          -  Uncontrolled type 1 or type 2 diabetes mellitus

          -  History of coronary artery disease (CAD), CAD-equivalent disease

          -  Familial hypercholesterolemia or has undergone LDL apheresis

          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoproteins

          -  Has had a gastrointestinal tract bypass, or other significant intestinal malabsorption

          -  History of cancer within the past 5 years (except for successfully treated
             dermatological basal cell or squamous cell carcinoma or in situ cervical cancer)

          -  Human Immunodeficiency Virus (HIV) positive

          -  History of drug/ alcohol abuse within the past 5 years or psychiatric illness not
             adequately controlled and stable on pharmacotherapy

          -  Consumes more than 25 g of alcohol per day

          -  Currently following an excessive weight reduction diet

          -  Currently engages in a vigorous exercise regimen (e.g.; marathon training, body
             building training etc.) or intends to start training during the study

          -  Hypersensitivity or intolerance to Ezetimibe or Rosuvastatin

          -  Myopathy or rhabdomyolysis with Ezetimibe or any statin

          -  Pregnant or lactating

          -  Taking any other investigational drugs and/or has taken any investigational drugs
             within 30 days
Clinical trial NCT02742519 (phase 3, status: terminated)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: ivacaftor, placebo
SMILES: CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    low enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female with confirmed diagnosis of CF.

          -  Must have 1 of the following CFTR gating mutations on at least 1 allele: G551D, G178R,
             S549N, S549R, G551S, G1244E, S1251N, S1255P, or G1349D.

          -  Hematology, serum chemistry, and coagulation at Screening with no clinically
             significant abnormalities or concomitant diagnosis that would interfere with the LCI
             and CT scan study assessments, as judged by the investigator.

        Exclusion Criteria:

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 4 weeks before Day 1

          -  Any clinically significant laboratory abnormalities at the Screening Visit that would
             interfere with the study assessments or pose an undue risk for the subject (in the
             opinion of the investigator)

          -  Abnormal liver function, at Screening, defined as ≥3 × upper limit of normal (ULN), of
             any 3 or more of the following: serum aspartate transaminase (AST), serum alanine
             transaminase (ALT), gamma-glutamyl transpeptidase (GGT), serum alkaline phosphatase
             (ALP), and total bilirubin

          -  History of solid organ or hematological transplantation

          -  Any clinically significant "non-CF-related" illness within 2 weeks before Day 1

          -  Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A
             within 2 weeks before Day 1

          -  Participation in a clinical study involving administration of either an
             investigational or a marketed drug within 30 days or 5 terminal half-lives (whichever
             is longer or as determined by the local requirements) before Screening
Clinical trial NCT02743234 (phase 3, status: completed)
Conditions: clostridium difficile infection
ICD codes: A05.2, A04.71, A04.72, B96.7
Drugs: fidaxomicin, vancomycin
SMILES: CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(CC)C(Cl)=C(O)C(Cl)=C3O)[C@H](O)[C@@H]2OC)\C(=O)OC(C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O, CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

        1. Relapse of Clostridium difficile infection with previous trial of vancomycin or
        fidaxomicin

        Exclusion Criteria:

          1. Pregnancy or breastfeeding

          2. Does not speak or understand the Danish language

          3. Current antibiotic treatment other than metronidazole, vancomycin, fidaxomicin

          4. fulminant colitis which contraindicates medical treatment

          5. physician's evaluation that the patient cannot tolerate project inclusion
Clinical trial NCT02744196 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo, methotrexate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

        Written informed consent. Age from 18 to 80 years. Rheumatoid arthritis diagnosed at least
        6 months before informed consent signing Presence of more than 8 swollen and more than 8
        painful joints at screening. C-reactive protein 7 mg/l or more AND/OR erythrocyte
        sedimentation rate 28 mm/hour or more.

        Antibodies to citrullinated cyclic peptide 20 U/ml or more AND/OR rheumatoid factor-IgM
        higher than upper normal limit.

        Documented regular methotrexate intake for 12 weeks, stable dose from 10 to 25 mg/week
        during last 4 weeks before signing informed consent.

        Exclusion Criteria:

        Methotrexate intolerance. Felty's syndrome. Patient functional status - IV class according
        to ACR. Previous use of biologic drugs to treat rheumatoid arthritis, biologic drugs that
        deplete CD20-lymphocytes, azathioprine use in the last 28 days prior to informed consent
        signing, leflunomide use in the last 8 weeks prior to informed consent signing,
        sulphasalazine/hydroxyquinoline use in the last 28 days prior to informed consent signing,
        intraarticular use of corticosteroids in the last 4 weeks prior to informed consent
        signing, patient requires prednisolone (or analogues) in a dose more than 10 mg/day or dose
        is unstable during 4 weeks prior to informed consent signing, requirement in non-steroid
        antiinflammatory drugs if their dose was not stable during last 8 weeks prior to informed
        consent signing.

        Patient has inflammatory joint disease otherwise than rheumatoid arthritis or systemic
        autoimmune diseases.

        Full list of inclusion and exclusion criteria can be found in Study Protocol.
Clinical trial NCT02749994 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: rosuvastatin, ezetimibe
SMILES: CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. 19 ~ 79 years old

          2. Patients who confirmed hypercholesterolemia.

          3. Patients who requiring drug therapy according to NCEP ATP(National Cholesterol
             Education Program Adult Treatment Panel) III Guideline at Visit2.

          4. Patients with Triglyceride< 400 at Visit 2.

          5. Patients who have a wash-out period over 4 weeks for other drugs that can affect lipid
             profile.(Patients who have lipid regulators should have washout period over six weeks)

          6. Patients who agreed to participate in the trial

        Exclusion Criteria:

          1. Patients who have a history of myopathy or rhabdomyolysis by statin treatment or
             hypersensitivity to statin HMG CoA(3-hydroxy-3-methylglutaryl-coenzyme) reductase
             inhibitors) or ezetimibe.

          2. A heavy alcohol consumer. (alcohol > 25 units/week)

          3. Patients with severe renal disease. (creatinine ≥ 2.0 mg/dL)

          4. Patients with active liver disease and AST(aspartate transaminase) or ALT(alanine
             transaminase) > 2 times of upper limit of normal range.

          5. Patients with CPK(creatine phosphokinase) > 2 x upper limit of normal range.

          6. Patients who have a endocrine or metabolic diseases known to affect the serum
             phospholipid or lipoprotein.

          7. Patients with HIV(human immunodeficiency virus positive.

          8. Patients who have a acute arteriopathy.

          9. Patients with uncontrolled hypertension.

         10. Patients who have hereditary problems such as galactose intolerance, Lapp lactase
             deficiency, or glucose-galactose malabsorption.

         11. Patients who have a drugs absorption disorder by gastrointestinal surgery or
             gastrointestinal disorder.

         12. Patients with tumor.

         13. Patients who have hormonal therapy.

         14. Pregnancy or breastfeeding patients who don't agree to use adequate contraception.

         15. Patients who are judged unsuitable to participate in this study by investigator.

         16. Patients taking other clinical trial drugs within 30 days from the time of visit for
             screening.
Clinical trial NCT02750293 (phase 3, status: completed)
Conditions: vitamin d deficiency
ICD codes: E55.9, D51.0, D51.1, D51.3, D51.8, D51.9, E50.0
Drugs: cholecalciferol, placebo
SMILES: CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  participated in The 7th survey in The Tromsø study

          -  vitamin D deficiency

        Exclusion Criteria:

          -  primary hyperparathyroidism

          -  granulomatous disease

          -  reduced kidney function

          -  systolic blood pressure > 174 mmHg

          -  diastolic blood pressure > 104 mmHg

          -  diabetes

          -  renal stones last 5 years

          -  use of solarium on regular basis

          -  planned holidays in tropical areas

          -  clinical depression

          -  clinical signs of vitamin D deficiency (muscle weakness)

          -  use of vitamin D supplements

          -  serious illness
Clinical trial NCT02752074 (phase 3, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: pembrolizumab + epacadostat, pembrolizumab + placebo
SMILES: NS(=O)(=O)NCCNC1=NON=C1\C(NC1=CC(Br)=C(F)C=C1)=N\O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have histologically or cytologically confirmed melanoma

          -  Have unresectable Stage III or Stage IV melanoma, as per AJCC staging system not
             amenable to local therapy

          -  A minimum of 1 measurable lesion by CT or MRI

          -  Provide a baseline tumor biopsy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

        Exclusion Criteria:

          -  Has received prior systemic treatment for unresectable or metastatic melanoma (except
             BRAF directed therapy)

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             IDO1 inhibitor or any other antibody or drug specifically targeting checkpoint
             pathways other than anti-CTLA-4 which is permitted in the adjuvant setting

          -  Has received prior adjuvant therapy, monoclonal antibody or an investigational agent
             or device within 4 weeks or 5 half-lives (whichever is longer)

          -  Has an active infection requiring systemic therapy

          -  Has known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)

          -  Has known history of or is positive for Hepatitis B or Hepatitis C

          -  Is pregnant or breastfeeding or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 120 days
             after the last dose of study treatment
Clinical trial NCT02754882 (phase 3, status: completed)
Conditions: lung cancer, non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: bevacizumab, sb8, carboplatin, paclitaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          1. Aged ≥ 18 years

          2. ECOG performance status of 0-1

          3. Histologically-confirmed metastatic or recurrent non-squamous non-small cell lung
             cancer

          4. At least one measurable lesion according to RECIST v1.1.

          5. Able to receive bevacizumab, carboplatin and paclitaxel based on adequate laboratory
             and clinical parameters

        Exclusion Criteria:

          1. Diagnosis of small cell carcinoma of the lung or squamous cell carcinoma

          2. Sensitizing EGFR mutations or ALK rearrangements

          3. Increased risk of bleeding determined by investigator based on radiographic / clinical
             findings

          4. History of systemic chemotherapy administered in the first-line setting for metastatic
             or recurrent disease of NSCLC.
Clinical trial NCT02757352 (phase 3, status: completed)
Conditions: axial spondyloarthritis
ICD codes: M45.A1, M45.A2, M45.A3, M45.A4, M45.A5, M45.A6, M45.A7
Drugs: ixekizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Are ambulatory.

          -  Diagnosis of nonradiographic axial spondyloarthritis (nr-axSpA) and fulfilling the
             2009 Assessment of Spondyloarthritis International Society (ASAS) classification
             criteria.

          -  Have a history of back pain ≥3 months with age at onset <45 years.

          -  Have active nr-axSpA defined as BASDAI ≥4 and total back pain ≥4 on a numeric rating
             scale (NRS) at screening and baseline.

          -  Have objective signs of inflammation by presence of sacroiliitis on MRI and/or
             presence of elevated C-reactive protein (CRP).

          -  In the past had an inadequate response to at least 2 non-steroidal anti-inflammatory
             drugs (NSAIDS) for duration of 4 weeks or cannot tolerate NSAIDS.

          -  If taking NSAIDS be on stable dose for at least 2 weeks prior to randomization.

          -  Have a history of prior therapy for axSpA for at least 12 weeks prior to screening.

        Exclusion Criteria:

          -  Have radiographic sacroiliitis fulfilling the 1984 modified New York criteria.

          -  Have received any prior, or are currently receiving treatment with biologics, tumor
             necrosis factor inhibitors or other immunomodulatory agents.

          -  Have received a live vaccine within 12 weeks or have had a vaccination with Bacillus
             Calmette-Guerin (BCG) within the past year.

          -  Have an ongoing or serious infection within the last 12 weeks or evidence of active
             tuberculosis.

          -  Have a compromised immune system.

          -  Have any other serious and/or uncontrolled diseases.

          -  Have either a current diagnosis or a recent history of malignant disease.

          -  Have had major surgery within 8 weeks of baseline, or will require surgery during the
             study.

          -  Are pregnant or breastfeeding.

          -  Have evidence of active anterior uveitis (an acute episode) within the last 42 days
             prior to baseline randomization.
Clinical trial NCT02762578 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/insulin aspart, biphasic insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities. Trial-related
             activities are any procedures that are carried out as part of the trial, including
             activities to determine suitability for the trial

          -  Male or female at least 18 years of age

          -  Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months

          -  Insulin treated subjects on current treatment: basal insulin, premixed insulin or a
             self-mixed insulin regimen, all administered once daily (OD) or BID with or without
             metformin. The treatment regimen should have remained unchanged for at least 8 weeks
             prior to randomisation

          -  HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis

          -  Body mass index (BMI) equal or below 40.0 kg/m^2

        Exclusion Criteria:

          -  Treatment with sulphonylureas, meglitinides, DPP-4 inhibitors, alpha-glycosidase
             inhibitors within 8 weeks prior to screening (Visit 1) or thiazolidinediones (TZDs) or
             GLP-1 receptor agonists within 12 weeks prior to screening (Visit 1)

          -  Anticipated change in concomitant medication known to interfere significantly with
             glucose metabolism, such as systemic corticosteroids, beta-blockers and monoamine
             oxidase (MAO) inhibitors

          -  Anticipated significant lifestyle changes during the trial according to the discretion
             of the investigator, e.g. shift work (including permanent night/evening shift
             workers), as well as highly variable eating habits

          -  Cardiovascular disease, within the last 6 months prior to screening (Visit 1), defined
             as: stroke; decompensated heart failure NYHA1 class III or IV; myocardial infarction;
             unstable angina pectoris; or coronary arterial bypass graft or angioplasty

          -  Any clinically significant disease or disorder, except for conditions associated with
             type 2 diabetes, which in the investigator's opinion could interfere with the results
             of the trial

          -  Previous participation in this trial. Participation is defined as screened.

          -  Known or suspected hypersensitivity to trial products or related products
Clinical trial NCT02762838 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: methotrexate, folic acid
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Active rheumatoid arthritis according to criteria of American College of
             Rheumatologists (2010), that was diagnosed at least 6 months prior to screening.

          -  Active rheumatoid arthritis at screening despite of therapy with methotrexate for 3
             last months.

          -  Use of methotrexate in stable dose for at least 4 weeks before screening (10-25 mg per
             week).

          -  History of ineffective treatment with basic antiinflammatory drugs (including
             methotrexate).

        Exclusion Criteria:

          -  Previous therapy of rheumatoid arthritis with monoclonal antibodies (including
             anti-tumor necrosis factor drugs)

          -  Felty's syndrome

          -  Functional status - class IV according to ACR classification (1991)

          -  Low activity of rheumatoid arthritis (DAS28-CRP(4) index less than 3.2)

          -  Patient needs corticosteroids in a dose more than 10 mg (recalculated to prednisolone)
             before signing informed consent.

          -  Patients needs equal of less than 10 mg prednisolone but the dose was not stable for
             last 4 weeks prior to infliximab treatment

          -  Prior use of disease-modifying antirheumatic drugs including methotrexate,
             sulfasalazin, chloroquine or hydroxychloroquine for up to 4 weeks before
             randomization.

          -  Prior use of alkylating agents for up to 12 months prior to signing informed consent.

          -  Intraarticular use of corticosteroids for up to 4 weeks before randomization.

          -  Prior use of live or attenuated vaccines for up to 8 weeks before signing informed
             consent.

          -  Diagnosis of tuberculosis.

          -  Body mass more than 130 kg.